April 25, 2017 6:26pm
Cell therapy equities are carrying more downside risk than upside safety at this point in time and I’m worried …
As traders cover their short positions, what are algorithms relying on and ETFs adjusting exposure to – the oversold or overbought?
As the sector’s financial results a.k.a. earnings or LPS <loss per share> announcements have yet to start and when they do their impact will be felt
Pre-open indications: 3 hits and 5 miss - I admit there was some money left on the table which is always an argument about risk – it’s all about selling into strength and strengthening a cell therapy portfolio
The truth is harsh, but reality is what it is …
I answer one question, in which company should investors commit and keep their money
RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.
Henry’omics:
From the pre-open’s investor’s newsletter “Every once in a while, the cell therapy sector catches a break where technicals, fundamentals and sentiment all fall into line, but they are always an easy target after a surge. This week may be one of those rare times when the planets are aligned however, I like to be prepared even IF I leave money on the table – to me being early is the key!”
Reiterating, “How many times have we been long which has left us “gonged” in the past!”
Speculation is "blowing in the wind"
We NEED to get back to fundaments …
What analytics were there today and why it was important in today’s sector outcomes?
- One answer – … The DOW closed up +232.23 or +1.12% to 20,996.12 while the NASDAQ closed up +41.67 or +0.70% to 6,025.49 … It's certainly an emotional influence, but investors need to be careful of this newest apex!
Q1/17 cell therapy sector results are in the making and spending patterns, cash positions and clinical results will be on parade!
- Today’s highs disrupt the past tests of the range bottoms; the question is the follow-on days of support!
I will also point to the alternative to the week’s advance/decline lines and positive/negative closes …
The cell therapy sector’s record after the last 5 days (of 43 covered companies):
· Tuesday closed POSITIVE with 28 decliners, 11 advancers and 4 flats
· Monday closed POSITIVE with 10 decliners, 32 advancers and 1 flat;
· Friday closed NEGATIVE with 35 decliners, 5 advancers and 3 flats;
· Thursday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;
· Wednesday closed POSITIVE with 9 decliners, 29 advancers and 5 flats;
· Last Tuesday closed NEGATIVE with 31 decliners, 10 advancers and 2 flat;
… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.8 …
· As Monday traded 10.9 – down -25.6% followed by Friday trading near 14.67 after Thursday’s near 14, Wednesday’s near 14.98 post last Tuesday’s near 15.04;
The iShares Russell 2000 (IWM) indicated a positive +0.32% at the pre-open was and closed UP +0.97%;
… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed UP +1.31%
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was positive with an A/DL of 30/9 and 4 flats;
· The mid-day stayed positive with an A/DL of 26/15 and 2 flat;
· The close was positive with an A/DL of 28/11 and 4 flats;
… Decliners ranged from -0.48% <FCSC> to -9.20% <NWBO> in 11 equities;
… Gainers ranged from +0.41% <BSTG> to +10.47% <SGMO> in 28 equities;
Pre-open indications: 3 hits and 5 miss
- Asterias Biotherapeutics (NYSEMKT: AST) closed up +$0.35 – miss;
- bluebird bio (BLUE) closed up +$2.10 – miss;
- Capricor (CAPR) closed +$0.14 – hit;
- Cellectis SA (CLLS) closed up +$0.26 – miss;
- Juno Therapeutics (JUNO) closed up +$0.13 – miss;
- Kite Pharma (KITE) closed down -$1.68 – hit;
- Mesoblast (MESO) closed up +$0.20 – hit;
- Spark Therapeutics (ONCE) closed up +$2.08 – miss;
Percentage gainers:
· Sangamo (SGMO) +10.47% after Monday’s +6.17%,
· Asterias Biotherapeutics (NYSEMKT: AST) +10.29% after Monday’s+9.68%,
· BioTime (NYSEMKT: BTX) +7.19%,
· Capricor (CAPR) +4.53%,
· Histogenics (HSGX) +4.29%,
Percentage losers:
· Kite Pharma (KITE) -2.04%,
· Regenxbio (RGNX) -2.79% after Monday’s +4.62%,
· Neuralstem (CUR) -1.97%,
· Cytori (CYTX) -3.64%,
· ImmunoCellular (NYSEMKT: IMUC) -1.32%,
Dollar gainers:
· Bluebird bio (BLUE) +$2.10 after Monday’s +$3.25,
· Spark Therapeutics (ONCE) +$2.08 after Monday’s +$2.34,
· Intrexon (XON) +$0.86,
· Sangamo (SGMO) +0.45,
· Stemline (STML) +$0.35,
Dollar losers:
· Kite Pharma (KITE) -$1.68,
· Regenxbio (RGNX) -0.60,
· Neuralstem (CUR) -0.10,
· Cytori (CYTX) -0.04,
· ImmunoCellular (NYSEMKT: IMUC) -$0.03,
Flats:
· Athersys (ATHX),
· Verastem (VSTM)
· Vericel (VCEL),
· ReNeuron (RENE.L)
Volume standouts versus 3 month averages:
· uniQure (QURE),
· Cellectis SA (CLLS),
· Applied genetic technologies (AGTC),
· Opexa (OPXA),
· Regenxbio (RGNX),
· BioTime (NYSEMKT: BTX),
· AxoGen (AXGN),
· Asterias Biotherapeutics (NYSEMKT: AST),
· Sangamo (SGMO),
· MiMedx (MDXG),
· Northwest Bio (NWBO),
· Capricor (CAPR),
· ReNeuron (RENE.L)
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
